ADMA Biologics

ADMA Biologics is a prominent commercial biopharmaceutical company established in 2004, dedicated to the development, manufacturing, and marketing of specialty plasma-derived therapeutics. The organization focuses on providing essential, life-saving treatments for immunodeficient patients who are at high risk for serious infections. By utilizing advanced human plasma purification techniques, the company addresses critical medical needs through its integrated commercial platform. Meet ADMA Biologics's team to understand the leadership and scientific expertise driving these clinical-stage biotechnology advancements in the competitive healthcare landscape.

Currently operating with 500-1,000 employees, the company maintains a sophisticated infrastructure designed to support its end-to-end commercialization and manufacturing efforts. ADMA Biologics leverages its deep expertise in plasma-derived products to deliver novel immune globulin therapies that improve patient outcomes. Learn about ADMA Biologics's global headquarters for detailed information regarding their primary operational footprint in Ramsey, New Jersey, and their broader strategic presence across North America. This facility serves as the central hub for their ongoing research, development, and commercial operations.

Publicly traded under the ticker NASDAQ: ADMA, the company has demonstrated consistent growth within the biopharmaceutical sector. With annual revenue reaching $509.9M, the firm continues to strengthen its market position against key competitors such as FFF Enterprises, Insmed, and Ultragenyx. Explore financial highlights to review the company's comprehensive funding history, including various debt and equity offerings that have successfully fueled its therapeutic pipeline and commercial expansion. These financial metrics underscore the company's stability and its commitment to long-term value creation for stakeholders in the global healthcare market.